Skip to main content
Download PDF

Therapeutic potential of mitochondrial transplantation in modulating immune responses post-cardiac arrest: a narrative review

Journal of Translational Medicine volume 22, Article number: 230 (2024) Cite this article

Abstract

Background

Mitochondrial transplantation (MTx) has emerged as a novel therapeutic strategy, particularly effective in diseases characterized by mitochondrial dysfunction. This review synthesizes current knowledge on MTx, focusing on its role in modulating immune responses and explores its potential in treating post-cardiac arrest syndrome (PCAS).

Methods

We conducted a comprehensive narrative review of animal and human studies that have investigated the effects of MTx in the context of immunomodulation. This included a review of the immune responses following critical condition such as ischemia reperfusion injury, the impact of MTx on these responses, and the therapeutic potential of MTx in various conditions.

Results

Recent studies indicate that MTx can modulate complex immune responses and reduce ischemia–reperfusion injury post-CA, suggesting MTx as a novel, potentially more effective approach. The review highlights the role of MTx in immune modulation, its potential synergistic effects with existing treatments such as therapeutic hypothermia, and the need for further research to optimize its application in PCAS. The safety and efficacy of autologous versus allogeneic MTx, particularly in the context of immune reactions, are critical areas for future investigation.

Conclusion

MTx represents a promising frontier in the treatment of PCAS, offering a novel approach to modulate immune responses and restore cellular energetics. Future research should focus on long-term effects, combination therapies, and personalized medicine approaches to fully harness the potential of MTx in improving patient outcomes in PCAS.

Background

Mitochondrial transplantation (MTx) is an emerging therapeutic strategy demonstrating profound efficacy in a spectrum of diseases, primarily those rooted in mitochondrial dysfunction [1, 2]. This cutting-edge technique involves the transfer of functional mitochondria from healthy donor to compromised recipient tissues, effectively restoring mitochondrial function, and ameliorating disease progression [3,4,5,6]. Moreover, recent discoveries regarding the natural, extracellular transfer of mitochondria between cells open new therapeutic vistas [7]. With its applicability extending to both genetic and acquired disorders, MTx represents a transformative approach for addressing the mitochondrial insufficiencies central to disease pathogenesis [8]. This modality holds substantial promise for future clinical translation, with the potential to significantly enhance patient outcomes.

Cardiac arrest (CA) poses a multifaceted clinical challenge, characterized by systemic ischemia–reperfusion (IR) injury, which triggers a cascade of intricate physiological alterations to vital organs [9,10,11,12]. Among these multifaceted changes, the activation of immune responses is increasingly recognized as a pivotal determinant [13,14,15]. In addition, accumulating evidence implicates IR-induced mitochondrial dysfunction as a key pathophysiological mechanism during the post-CA phase [16,17,18]. This mitochondrial dysfunction might be instrumental in driving the observed aberrations in immune cell function following CA. We have recently demonstrated that MTx improves outcomes post-CA in a rodent model [19]. Of note, emerging data suggest that MTx possibly serves a dual purpose: it not only replenishes dysfunctional mitochondria but also modulates immune responses. Thus, deep insights into the interplay between MTx and immune response during IR hold the potential to revolutionize therapeutic strategies for IR injury. In this context, we offer a comprehensive narrative review aimed at elucidating the role of MTx in modulating immune responses post-CA.

Animal studies elucidating immune responses following cardiac arrest and resuscitation

While the immune system is essential for infection control and homeostasis, CA resuscitation disrupts immunological functions in a complex manner. It triggers a systemic inflammatory response, characterized by a surge in inflammatory mediators and cytokines. While this response is integral for tissue repair and cellular debris clearance, its dysregulation can exacerbate organ damage and lead to post-CA syndrome (PCAS). Numerous studies corroborate that CA often results in immune alterations, evidenced by increased neutrophil and monocyte activity, compromised lymphocyte proliferation, and altered cytokine profiles [14, 20, 21]. These disruptions further exaggerate IR injury after CA, emphasizing the urgent need for innovative strategies to mitigate immune-related complications and improve post-CA outcomes.

The intricate relationship between CA and immune responses in the context of brain injury has been elucidated [22]. Upon injury, microglia, the brain's resident immune cells, swiftly activate, releasing substances with dual cytoprotective and cytotoxic properties, including pro-inflammatory cytokines such as interleukin (IL)-1ꞵ, IL-6, IL-10, and interferon (IFN)-γ [23,24,25]. This activation triggers the infiltration of peripheral immune cells, such as neutrophils, macrophages, and T lymphocytes, exacerbating neuronal damage [25,26,27]. Astrocytes, supportive brain cells, also respond to hypoxic stress by releasing both neuroprotective and pro-inflammatory cytokines, potentially leading to delayed neuronal death [28, 29]. Notably, neutrophils and T lymphocytes, including CD4+ and CD8+ T cells, participate in cerebral IR injury, promoting inflammation, brain infarction, and neurological deficits [30,31,32]. While these immune responses initially aim to safeguard the brain, they can paradoxically contribute to ongoing neuronal injury and delayed damage [33].

In the context of global cerebral ischemia caused by CA resuscitation, the traditionally immune-privileged brain experiences rapid infiltration of pro-inflammatory T cells [34]. These infiltrating cells are predominantly CD4+ T lymphocytes, which not only attain an activated state but sustain their presence in the cerebral parenchyma for an extended period of time, up to 72 h post resuscitation [35, 36]. In studies of experimental ischemic stroke, the timing of immune cell entry into the brain has been well-documented. Specifically, neutrophils are the first to arrive, presenting rapidly within several hours after ischemic strokes, followed by lymphocytes which appear 12 to 24 h after neuronal ischemic injury [35,36,37,38]. This lymphocytic infiltration is concomitant with a marked exacerbation of neuronal cell death in the hippocampal CA1 region, a phenomenon that may be mediated by the secretion of pro-inflammatory cytokines such as TNF-α and IFN-γ [37, 39]. Consequently, these observations suggest that modulating T cell infiltration and the ensuing immune cascade in the aftermath of CA could serve as a novel therapeutic avenue [32].

In a study using a swine CA model, increased pro-inflammatory cytokines, such as IL-6 and TNF-α, were observed in renal tissue post-CA. T lymphocytes, specifically CD4+ and CD8+ T cells, were shown to infiltrate renal tissue, contributing to post-CA renal injury. Severity of renal injury correlated with T lymphocyte infiltration and cytokine production, with prolonged resuscitation leading to more pronounced damage [40]. Further, regulatory T cells (Treg), responsible for immune regulation and inflammation suppression, decreased in renal tissue post-CA, disrupting a balanced immune response. These observations suggest that activation of T lymphocytes, altered Treg function, and immune disruption can contribute to post-CA renal damage, offering potential therapeutic targets for mitigating organ injury after CA resuscitation.

Furgeson et al. demonstrated that peripheral mitochondrial bioenergetic profiles correlate with degree of injury post CA. Using a piglet model of pediatric CA, these authors studied the association of peripheral platelets on brain injury after CA resuscitation [41]. They revealed that CA leads to significant enhancements in platelet mitochondrial bioenergetics, primarily through increased respiration via complex II of the electron transport system [41]. Platelet mitochondrial respiratory capacity and efficiency also rise post-CA. This suggests that platelet mitochondrial respiration, measured from peripheral blood, may serve as a non-invasive biomarker for assessing post-CA cerebral bioenergetic dysfunction. Given mitochondrial damage-associated molecular patterns (DAMPs) ability to activate platelets and prompt inflammation [42, 43], CA may induce platelet mitochondrial biogenesis, but increased functional respiration appears to result from post-translational modifications and other mechanisms.

Another study showed that CA activates the hypothalamic–pituitary–adrenal (HPA) axis, a vital stress response pathway, resulting in the release of stress hormones, including cortisol, which modulate immune responses [44]. Prolonged CA resuscitation duration directly correlated with increased severity of immunosuppression and immune dysfunction. A mechanistic link between post-CA immunosuppression and the HPA axis was supported by evidence that glucocorticoid treatment exacerbates immunosuppression. Conversely, RU486 (Mifepristone), a synthetic steroid that acts as a glucocorticoid receptor antagonist and a progesterone receptor antagonist, was found to mitigate lymphopenia and atrophy, improving CA outcomes.

A mouse model reveals that asphyxia CA severely impairs lymphopoiesis, reducing systemic lymphocyte production in the bone marrow and thymus, which are critical for lymphocyte development [45]. This impairment persists after resuscitation and, importantly, this study uncovered potential mechanisms behind this impairment. They found that CA increased reactive oxygen species (ROS) and DNA damage in the bone marrow and thymus, known to negatively impact lymphocyte development. Additionally, IL-7, crucial for lymphocyte development, significantly decreased in these organs post-CA, potentially contributing to the observed lymphopoiesis impairment.

The above-mentioned animal studies demonstrate that the multifaceted interplay between CA resuscitation and immune responses presents a complex landscape that is crucial for understanding PCAS and organ damage. The evidence suggests that CA resuscitation triggers a systemic inflammatory response that, while essential for tissue repair and cellular debris clearance, can lead to immune dysregulation and exacerbate IR injuries. This is particularly evident in the brain and systemic circulation, where immune cells such as T lymphocytes and neutrophils, as well as inflammatory cytokines, play pivotal roles. The activation of the HPA axis and its modulation by glucocorticoids, as well as peripheral platelet mitochondrial bioenergetics and lymphopoiesis impairment, further add complexity to the immune landscape post-CA. These findings collectively underscore the urgent need for innovative strategies aimed at modulating immune responses to improve outcomes in post-CA care.

Prognostic assessment of post-cardiac arrest outcomes through targeted evaluation of immune response mechanisms

In a study of out-of-hospital CA (OHCA) survivors, Qi et al. studied presepsin as a prognostic biomarker for early immune changes [46]. They discovered that presepsin levels surged after return of spontaneous circulation (ROSC), with higher levels associated with unfavorable neurological outcomes and mortality. Both presepsin and procalcitonin exhibited distinct patterns in the first three days post-ROSC among patients with different outcomes. This combination of biomarkers was identified as independent predictors of 28-day survival and favorable neurological outcomes. Additionally, the study examined monocyte markers, CD14 and HLA-DR, revealing that CD14 expression increased on day 1 but decreased on day 3, while HLA-DR expression consistently decreased on both days 1 and 3. These changes correlated with TLR-4 expression. Together these findings support a transient hyperactivity and subsequent dysfunction of innate immune functions.

In a study examining the relationship between immune responses and survival in patients with CA, investigators focused on CD73-expressing lymphocytes, a heterogenous population of adenosine-producing CD4+ and CD8+ T cells, naïve and memory B cells, and follicular dendritic cells [47,48,49,50]. Their investigation aimed to determine if the levels of these lymphocytes could serve as a survival predictor, revealing that survivors had significantly higher circulating CD73-expressing lymphocyte levels compared to non-survivors [47]. In addition, the number of these lymphocytes correlated with favorable neurological outcomes in survivors. Higher CD73 expression on lymphocytes led to increased adenosine production, which possesses anti-inflammatory and tissue-protective properties [47], suggesting that elevated CD73-expressing lymphocyte levels are associated with improved survival and neurological function in patients with CA. The role of CD73 as a marker of the body’s ability to quell immune responses is further supported by both animal and human studies that employ antibody-mediated experimental blockade to reactivate adaptive immune responses in cancer [50, 51].

A recent study of serum samples collected from Swedish patients enrolled in the targeted temperature management (TTM) trial has identified additional, potential biomarkers through proteomic analysis [52]. Comparing patients with good and poor neurological outcome 6 months following CA, the study proposed the utility of proteins known to be implicated in immune programs, including kallistatin and angiotensinogen, in neuroprognostication and treatment monitoring. While these markers have not been validated or investigated in larger cohorts, further studies may help to advance them into clinical practice.

Human studies aiming to regulate excessive immune responses following cardiac arrest resuscitation

Clinical studies highlight the potential of Cyclosporine A (CsA) and tocilizumab in modulating immune responses post-CA, offering new directions for PCAS treatment strategies [53]. CsA, when administered at the commencement of cardiopulmonary resuscitation (CPR), has demonstrated short-term benefits by reducing multi-organ dysfunction, supported by the CYRUS trial's findings on mitigating post-CA immune dysfunction without affecting survival in non-shockable OHCA cases [54, 55]. The IMICA trial further revealed tocilizumab's effectiveness in lowering inflammatory markers and cardiac injury indicators, although its impact on long-term outcomes and neurocognitive functions remains unclear [56, 57]. These findings suggest a promising role for these interventions in improving short-term outcomes, yet the long-term effects require further investigation.

Glucocorticoids, particularly hydrocortisone, have shown promise in various trials targeting CA patients, enhancing ROSC rates, reducing organ dysfunction, and improving survival [58, 59]. These steroids appear to lower inflammation by decreasing pro-inflammatory cytokines [60, 61]. Further, a prospective observational single-center study focused the immune responses and glucocorticoid receptor expression in patients with CA [62]. The study revealed that CA survivors exhibit lower glucocorticoid receptor levels in leukocytes, especially those with prolonged CA and adverse neurological outcomes, linking receptor downregulation with increased inflammation [62]. This suggests that early post-CA corticosteroid therapy might help regulate immune responses and improve patient outcomes by normalizing glucocorticoid receptor activity.

Therapeutic hypothermia and immune response after cardiac arrest resuscitation

TTM, inclusive of therapeutic hypothermia (TH), is the primary neuroprotective approach post-CA, with potential synergies with mitochondrial therapies to enhance recovery. While neuroprotective effects of TH are established, optimizing its application, including temperature and timing, is crucial to maximize benefits and minimize risks. Early and sustained TH is essential for improving outcomes, highlighting the need for strategic application [63].

Recent studies have explored the impact of induced hypothermia on post-CA immune modulation. Ultrafast hypothermia, applied immediately after CA, has been shown to reduce pro-inflammatory cytokines like IL-6 and TNF-α, suggesting its potential in mitigating PCAS-related inflammation [64]. However, the immunomodulatory effects of hypothermia are complex, with some studies indicating transient cytokine increases without significant changes in immune markers, such as HLA-DR [65, 66]. These findings point to the nuanced role of hypothermia in immune responses post-CA, underscoring the necessity for further research to clarify its therapeutic implications.

Therapeutic potential of mitochondrial transplantation for immune response modulation in various conditions

As summarized in Table 1 and depicted in Fig. 1, therapeutic potentials of MTx have been shown in various conditions. Based on the observation that cells can assimilate mitochondria from their surroundings, MTx has emerged as a strategy with the potential to modulate the immune response in various pathological conditions [67]. In cardiovascular disease the role of extracellular mitochondrial components has been highlighted, with their potential to regulate immune responses and promote cell survival, suggesting MTx as a new avenue for therapeutic intervention [68]. Furthermore, in several disease models, MTx has been shown to regulate the inflammatory response effectively. Studies using rodent sepsis models, for instance, demonstrated that MTx improved bacterial clearance and survival outcome, indicating immunomodulatory effects [69, 70]. MTx was associated with decreased bacterial burden, systemic inflammation, complement and coagulation cascades, and organ injury [69]. MTx also exhibits a bimodal immunomodulatory effect; it reduces immune cell apoptosis and immune paralysis, enhancing bacterial clearance and survival, while also attenuating hyperinflammatory responses early in sepsis [70]. This dual action suggests that MTx can regulate immune function by shifting cell metabolism, potentially offering a single therapeutic strategy for the dynamic immune changes in sepsis, from hyperinflammation to immune paralysis. A study on 22–24 month old rats with myocardial IR injury revealed that combining Coenzyme Q10 (ubiquinone; a lipid-soluble molecule functioning as an electron carrier in the mitochondrial electron transport chain) with MTx improved both short-term and long-term outcomes, with enhanced autophagic flux and reduced inflammatory response following the injury [71]. In another study, allogeneic MTx in rats with traumatic spinal cord injury showed promising therapeutic effects. Labeled mitochondria were present in the injured spinal cord for up to 28 days post transplantation. Rats receiving this treatment showed improved locomotor and sensory functions, reduced expression of dynamin-related protein 1, less demyelination, and alleviated cellular apoptosis and inflammation in the injured cord. These results suggest that early-stage allogeneic MTx in spinal cord injury can mitigate mitochondrial damage, neuroapoptosis, neuroinflammation, and oxidative stress, thereby enhancing functional recovery [72]. One study using mice lung IR injury model demonstrated that donor mitochondria either directly injected into the pulmonary artery or via nebulization attenuated neutrophil infiltration, interstitial edema, and apoptosis in lungs [73]. However, the study reported no significant differences in cytokines and chemokines levels in bronchoalveolar lavage fluid at 24 h post reperfusion between the groups that received MTx and those that did not. This suggests that the impact of MTx may be more pronounced in physical tissue changes rather than in the modulation of these specific inflammatory markers in this particular model at the measured time point.

Table 1 Summary of the mitochondrial transplantation studies described in the present review
Full size table
Fig. 1
figure 1

Therapeutic potential of mitochondrial transplantation in modulating immune responses. Created with BioRender.com

Full size image

The anti-inflammatory and regenerative capabilities of MTx have also been evidenced in a range of non-critical ill conditions. In chronic neurodegenerative diseases, MTx has been proposed as a means to counteract the chronic inflammation that contributes to neuronal damage, with the potential to alter the disease course in conditions such as Alzheimer's and Parkinson's disease (PD) [74]. In a mouse model, transplantation of healthy mitochondria into the hippocampus attenuated lipopolysaccharide (LPS)-induced depression-like behaviors by enhancing mitochondrial function, reducing oxidative stress and inflammatory cytokines, thereby suggesting potential therapeutic efficacy for depressive disorders linked to inflammation and mitochondrial dysfunction [75]. In tendinopathy, transplanted mitochondria have been shown to increase tenocyte integrity markers, reduce TNF-α to control levels and dramatically reduce IL-1β and IL-6 levels, thereby facilitating tissue regeneration [76]. Similarly, in osteoarthritis, mitochondria derived from bone marrow mesenchymal stem cells have been found to enhance chondrocyte function and stimulate mitochondrial biogenesis, contributing to joint health [77]. Human MSC-derived mitochondria have shown promise in attenuating LPS-induced inflammatory responses by inhibiting the nuclear factor kappa-light-chain-enhancer of activated B cells (NFκB) signaling pathway [78]. Further, a link between mitochondrial health in neurodevelopment and brain functioning in adulthood was established in a maternal immune activation model of schizophrenia in rats [79]. Intracerebral injection of allogenic, healthy mitochondria into the medial prefrontal cortex of adolescent rats revealed disparate initial changes in mitochondrial function and inflammatory responses between schizophrenic and control rats. These were associated with opposite effects in proteome alteration, monoamine turnover, neuronal sprouting and behavior in adulthood, dependent on disease state, supporting the therapeutic potential of MTx during adolescence in neurodevelopmental disorders.

As for potential adverse immune reactions due to MTx, studies have shown that autologous MTx, as applied in a rabbit model of ischemic cardiomyopathy and a porcine model of ischemia/reperfusion, did not elicit significant immune responses or elevate serum cytokine levels, suggesting its relative safety and low immunogenicity [80, 81]. Moreover, no discernible instances of direct or indirect, acute or chronic alloreactivity, allorecognition or DAMPs were observed following single or serial injections of either syngeneic or allogeneic mitochondria in mice [82]. Similarly, both autologous and allogenic MTx were executed without adverse effects in diverse models of organ ischemia reperfusion injury [4, 73, 83,84,85,86,87]. However, the safety and efficacy of autologous versus allogeneic MTx in humans, particularly in the context of immune responses, represent crucial domains necessitating future exploration.

Taken together, MTx represents a frontier in the modulation of the immune response, offering a novel approach to the treatment of a wide array of diseases characterized by inflammatory alterations. The ability to restore cellular energetics as well as modulate the immune system provides a unique therapeutic avenue, with the potential to revolutionize the management of critical illnesses, including PCAS. The dual efficacy of MTx in enhancing cellular energy and regulating immune responses after CA is illustrated in Fig. 2.

Fig. 2
figure 2

Therapeutic potential of mitochondrial transplantation in modulating immune responses post CA. Created with BioRender.com

Full size image

Future directions in mitochondrial transplantation for post-cardiac arrest syndrome

The promising results from preclinical and early clinical studies on MTx necessitate the expansion of further studies specifically investigating PCAS. Moreover, a deeper understanding of the mechanisms by which MTx modulates immune responses in the context of PCAS is essential. Future research should aim to elucidate the intricate interactions between transplanted mitochondria and various immune cells, and how these interactions influence the overall immune response post-CA. This includes studying the role of mitochondrial-derived DAMPs and their impact on inflammation and tissue repair. The presence and the degradation of circulating cell-free intact mitochondria originating from several cell types in plasma were demonstrated in both physiological and pathological conditions, which were presumed to be capable of activating immune cells and modulating an inflammatory response [88, 89]. Intravenously injected exogenous mitochondria were also demonstrated to distribute in various tissues including brain, liver, kidney, muscle and heart in experimental PD model mice, which prevented PD progress through increasing the activity of electron transport chain, decreasing ROS level, and preventing cell apoptosis and necrosis [90]. This suggests that MTx would benefit on the multi-organ injury in PCAS. Additionally, exploring the potential of MTx in modulating the balance between pro-inflammatory and anti-inflammatory responses could lead to more effective strategies for managing the complex immune dysregulation observed in PCAS.

Conclusions

The burgeoning field of MTx presents a novel and promising therapeutic avenue for addressing the complex pathophysiology of PCAS. By focusing on long-term effects, combination therapies, and a deeper understanding of the immunomodulatory mechanisms of MTx, this innovative treatment could revolutionize the management of PCAS. The ability of MTx to restore cellular energetics and modulate immune responses offers a unique and multifaceted approach to tackling the challenges of PCAS, potentially leading to enhanced survival rates, improved neurological outcomes, and better quality of life for patients. Further exploration to elucidate detailed mechanism and relationship between MTx and immune responses post-CA, which might pave the way to facilitate clinical implementation of MTx for patients suffering from CA pathophysiology, are warranted.

Availability of data and materials

Not applicable.

Abbreviations

ATP:

Adenosine triphosphate

CA:

Cardiac arrest

CPR:

Cardiopulmonary resuscitation

CsA:

Cyclosporine A

DAMPs:

Damage-associated molecular patterns

HPA:

Hypothalamic–pituitary–adrenal

IFN:

Interferon

IL:

Interleukin

IR:

Ischemia–reperfusion

LPS:

Lipopolysaccharide

MSC:

Mesenchymal stem cell

MTx:

Mitochondrial transplantation

NFκB:

Nuclear factor kappa-light-chain-enhancer of activated B cells

OHCA:

Out-of-hospital cardiac arrest

PCAS:

Post-cardiac arrest syndrome

PD:

Parkinson's disease

ROS:

Reactive oxygen species

ROSC:

Return of spontaneous circulation

TH:

Therapeutic hypothermia

Treg:

Regulatory T cells

TTM:

Targeted temperature management

References

  1. McCully JD, Cowan DB, Emani SM, Del Nido PJ. Mitochondrial transplantation: from animal models to clinical use in humans. Mitochondrion. 2017;34:127–34.

    Article  CAS  PubMed  Google Scholar 

  2. Park A, Oh M, Lee SJ, Oh KJ, Lee EW, Lee SC, Bae KH, Han BS, Kim WK. Mitochondrial transplantation as a novel therapeutic strategy for mitochondrial diseases. Int J Mol Sci. 2021. https://doi.org/10.3390/ijms22094793.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Zhang B, Gao Y, Li Q, Sun D, Dong X, Li X, Xin W, Zhang J. Effects of brain-derived mitochondria on the function of neuron and vascular endothelial cell after traumatic brain injury. World Neurosurg. 2020;138:e1–9.

    Article  PubMed  Google Scholar 

  4. Guariento A, Doulamis IP, Duignan T, Kido T, Regan WL, Saeed MY, Hoganson DM, Emani SM, Fynn-Thompson F, Matte GS, et al. Mitochondrial transplantation for myocardial protection in ex-situ-perfused hearts donated after circulatory death. J Heart Lung Transplant. 2020;39(11):1279–88.

    Article  PubMed  Google Scholar 

  5. Ko SF, Chen YL, Sung PH, Chiang JY, Chu YC, Huang CC, Huang CR, Yip HK. Hepatic (31) P-magnetic resonance spectroscopy identified the impact of melatonin-pretreated mitochondria in acute liver ischaemia-reperfusion injury. J Cell Mol Med. 2020;24(17):10088–99.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Hayashida K, Takegawa R, Shoaib M, Aoki T, Choudhary RC, Kuschner CE, Nishikimi M, Miyara SJ, Rolston DM, Guevara S, et al. Mitochondrial transplantation therapy for ischemia reperfusion injury: a systematic review of animal and human studies. J Transl Med. 2021;19(1):214.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Hayakawa K, Bruzzese M, Chou SH, Ning M, Ji X, Lo EH. Extracellular mitochondria for therapy and diagnosis in acute central nervous system injury. JAMA Neurol. 2018;75(1):119–22.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Roushandeh AM, Kuwahara Y, Roudkenar MH. Mitochondrial transplantation as a potential and novel master key for treatment of various incurable diseases. Cytotechnology. 2019;71(2):647–63.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Soar J, Becker LB, Berg KM, Einav S, Ma Q, Olasveengen TM, Paal P, Parr MJA. Cardiopulmonary resuscitation in special circumstances. Lancet. 2021;398(10307):1257–68.

    Article  PubMed  Google Scholar 

  10. Okuma Y, Becker LB, Hayashida K, Aoki T, Saeki K, Nishikimi M, Shoaib M, Miyara SJ, Yin T, Shinozaki K. Effects of post-resuscitation normoxic therapy on oxygen-sensitive oxidative stress in a rat model of cardiac arrest. J Am Heart Assoc. 2021;10(7): e018773.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Aoki T, Wong V, Endo Y, Hayashida K, Takegawa R, Okuma Y, Shoaib M, Miyara SJ, Yin T, Becker LB, et al. Bio-physiological susceptibility of the brain, heart, and lungs to systemic ischemia reperfusion and hyperoxia-induced injury in post-cardiac arrest rats. Sci Rep. 2023;13(1):3419.

    Article  ADS  CAS  PubMed  PubMed Central  Google Scholar 

  12. Aoki T, Wong V, Endo Y, Hayashida K, Takegawa R, Shoaib M, Miyara SJ, Choudhary RC, Yin T, Saeki K, et al. Insufficient oxygen inhalation during cardiopulmonary resuscitation induces early changes in hemodynamics followed by late and unfavorable systemic responses in post-cardiac arrest rats. FASEB J. 2023;37(7): e23001.

    Article  CAS  PubMed  Google Scholar 

  13. Slegtenhorst BR, Dor FJ, Rodriguez H, Voskuil FJ, Tullius SG. Ischemia/reperfusion Injury and its consequences on immunity and inflammation. Curr Transplant Rep. 2014;1(3):147–54.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Krychtiuk KA, Lenz M, Richter B, Hohensinner PJ, Kastl SP, Mangold A, Huber K, Hengstenberg C, Wojta J, Heinz G, et al. Monocyte subsets predict mortality after cardiac arrest. J Leukoc Biol. 2021;109(6):1139–46.

    Article  CAS  PubMed  Google Scholar 

  15. Ioannou A, Dalle Lucca J, Tsokos GC. Immunopathogenesis of ischemia/reperfusion-associated tissue damage. Clin Immunol. 2011;141(1):3–14.

    Article  CAS  PubMed  Google Scholar 

  16. Han F, Da T, Riobo NA, Becker LB. Early mitochondrial dysfunction in electron transfer activity and reactive oxygen species generation after cardiac arrest. Crit Care Med. 2008;36(11 Suppl):S447-453.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Aoki T, Okuma Y, Becker LB, Hayashida K, Shinozaki K. Methodological issue of mitochondrial isolation in acute-injury rat model: asphyxia cardiac arrest and resuscitation. Front Med (Lausanne). 2021;8: 666735.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Kuschner CE, Kim N, Shoaib M, Choudhary RC, Nishikimi M, Yin T, Becker LB, Hoppel CL, Kim J. Understanding physiologic phospholipid maintenance in the context of brain mitochondrial phospholipid alterations after cardiac arrest. Mitochondrion. 2021;60:112–20.

    Article  CAS  PubMed  Google Scholar 

  19. Hayashida K, Takegawa R, Endo Y, Yin T, Choudhary RC, Aoki T, Nishikimi M, Murao A, Nakamura E, Shoaib M, et al. Exogenous mitochondrial transplantation improves survival and neurological outcomes after resuscitation from cardiac arrest. BMC Med. 2023;21(1):56.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Weiser C, Schwameis M, Sterz F, Herkner H, Lang IM, Schwarzinger I, Spiel AO. Mortality in patients resuscitated from out-of-hospital cardiac arrest based on automated blood cell count and neutrophil lymphocyte ratio at admission. Resuscitation. 2017;116:49–55.

    Article  PubMed  Google Scholar 

  21. Uray T, Dezfulian C, Palmer AA, Miner KM, Leak RK, Stezoski JP, Janesko-Feldman K, Kochanek PM, Drabek T. Cardiac arrest induced by asphyxia versus ventricular fibrillation elicits comparable early changes in cytokine levels in the rat brain, heart, and serum. J Am Heart Assoc. 2021;10(5): e018657.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Xiang Y, Zhao H, Wang J, Zhang L, Liu A, Chen Y. Inflammatory mechanisms involved in brain injury following cardiac arrest and cardiopulmonary resuscitation. Biomed Rep. 2016;5(1):11–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Stoll G, Jander S, Schroeter M. Inflammation and glial responses in ischemic brain lesions. Prog Neurobiol. 1998;56(2):149–71.

    Article  CAS  PubMed  Google Scholar 

  24. Lucas SM, Rothwell NJ, Gibson RM. The role of inflammation in CNS injury and disease. Br J Pharmacol. 2006;147(Suppl 1):232–40.

    Google Scholar 

  25. Yenari MA, Kauppinen TM, Swanson RA. Microglial activation in stroke: therapeutic targets. Neurotherapeutics. 2010;7(4):378–91.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Aloisi F. Immune function of microglia. Glia. 2001;36(2):165–79.

    Article  CAS  PubMed  Google Scholar 

  27. Nakajima K, Kohsaka S. Microglia: activation and their significance in the central nervous system. J Biochem. 2001;130(2):169–75.

    Article  CAS  PubMed  Google Scholar 

  28. Swanson RA, Ying W, Kauppinen TM. Astrocyte influences on ischemic neuronal death. Curr Mol Med. 2004;4(2):193–205.

    Article  CAS  PubMed  Google Scholar 

  29. Ransom B, Behar T, Nedergaard M. New roles for astrocytes (stars at last). Trends Neurosci. 2003;26(10):520–2.

    Article  CAS  PubMed  Google Scholar 

  30. Shichita T, Sugiyama Y, Ooboshi H, Sugimori H, Nakagawa R, Takada I, Iwaki T, Okada Y, Iida M, Cua DJ, et al. Pivotal role of cerebral interleukin-17-producing gammadeltaT cells in the delayed phase of ischemic brain injury. Nat Med. 2009;15(8):946–50.

    Article  CAS  PubMed  Google Scholar 

  31. Price CJ, Menon DK, Peters AM, Ballinger JR, Barber RW, Balan KK, Lynch A, Xuereb JH, Fryer T, Guadagno JV, et al. Cerebral neutrophil recruitment, histology, and outcome in acute ischemic stroke: an imaging-based study. Stroke. 2004;35(7):1659–64.

    Article  CAS  PubMed  Google Scholar 

  32. Deng G, Carter J, Traystman RJ, Wagner DH, Herson PS. Pro-inflammatory T-lymphocytes rapidly infiltrate into the brain and contribute to neuronal injury following cardiac arrest and cardiopulmonary resuscitation. J Neuroimmunol. 2014;274(1–2):132–40.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Santana MA, Rosenstein Y. What it takes to become an effector T cell: the process, the cells involved, and the mechanisms. J Cell Physiol. 2003;195(3):392–401.

    Article  CAS  PubMed  Google Scholar 

  34. Iadecola C, Anrather J. The immunology of stroke: from mechanisms to translation. Nat Med. 2011;17(7):796–808.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Park TS, Gonzales ER, Gidday JM. Platelet-activating factor mediates ischemia-induced leukocyte-endothelial adherence in newborn pig brain. J Cereb Blood Flow Metab. 1999;19(4):417–24.

    Article  CAS  PubMed  Google Scholar 

  36. Stevens SL, Bao J, Hollis J, Lessov NS, Clark WM, Stenzel-Poore MP. The use of flow cytometry to evaluate temporal changes in inflammatory cells following focal cerebral ischemia in mice. Brain Res. 2002;932(1–2):110–9.

    Article  CAS  PubMed  Google Scholar 

  37. Yilmaz G, Arumugam TV, Stokes KY, Granger DN. Role of T lymphocytes and interferon-gamma in ischemic stroke. Circulation. 2006;113(17):2105–12.

    Article  PubMed  Google Scholar 

  38. Yilmaz G, Granger DN. Leukocyte recruitment and ischemic brain injury. Neuromolecular Med. 2010;12(2):193–204.

    Article  CAS  PubMed  Google Scholar 

  39. Liesz A, Zhou W, Mracsko E, Karcher S, Bauer H, Schwarting S, Sun L, Bruder D, Stegemann S, Cerwenka A, et al. Inhibition of lymphocyte trafficking shields the brain against deleterious neuroinflammation after stroke. Brain. 2011;134(Pt 3):704–20.

    Article  PubMed  Google Scholar 

  40. Tsivilika M, Doumaki E, Stavrou G, Sioga A, Grosomanidis V, Meditskou S, Maranginos A, Tsivilika D, Stafylarakis D, Kotzampassi K, et al. The adaptive immune response in cardiac arrest resuscitation induced ischemia reperfusion renal injury. J Biol Res (Thessalon). 2020;27:15.

    Article  CAS  PubMed  Google Scholar 

  41. Ferguson MA, Sutton RM, Karlsson M, Sjovall F, Becker LB, Berg RA, Margulies SS, Kilbaugh TJ. Increased platelet mitochondrial respiration after cardiac arrest and resuscitation as a potential peripheral biosignature of cerebral bioenergetic dysfunction. J Bioenerg Biomembr. 2016;48(3):269–79.

    Article  CAS  PubMed  Google Scholar 

  42. Yasui K, Matsuyama N, Kuroishi A, Tani Y, Furuta RA, Hirayama F. Mitochondrial damage-associated molecular patterns as potential proinflammatory mediators in post-platelet transfusion adverse effects. Transfusion. 2016;56(5):1201–12.

    Article  CAS  PubMed  Google Scholar 

  43. Zhang Q, Itagaki K, Hauser CJ. Mitochondrial DNA is released by shock and activates neutrophils via p38 map kinase. Shock. 2010;34(1):55–9.

    Article  PubMed  Google Scholar 

  44. Zhao Q, Shen Y, Li R, Wu J, Lyu J, Jiang M, Lu L, Zhu M, Wang W, Wang Z, et al. Cardiac arrest and resuscitation activates the hypothalamic-pituitary-adrenal axis and results in severe immunosuppression. J Cereb Blood Flow Metab. 2020. https://doi.org/10.1177/0271678X20948612.

    Article  PubMed  PubMed Central  Google Scholar 

  45. Wang W, Li R, Miao W, Evans C, Lu L, Lyu J, Li X, Warner DS, Zhong X, Hoffmann U, et al. Development and evaluation of a novel mouse model of asphyxial cardiac arrest revealed severely impaired lymphopoiesis after resuscitation. J Am Heart Assoc. 2021;10(11): e019142.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Qi Z, Zhang Q, Liu B, Shao F, Li C. Presepsin as a biomarker for evaluating prognosis and early innate immune response of out-of-hospital cardiac arrest patients after return of spontaneous circulation. Crit Care Med. 2019;47(7):e538–46.

    Article  CAS  PubMed  Google Scholar 

  47. Ryzhov S, May T, Dziodzio J, Emery IF, Lucas FL, Leclerc A, McCrum B, Lord C, Eldridge A, Robich MP, et al. Number of circulating CD 73-expressing lymphocytes correlates with survival after cardiac arrest. J Am Heart Assoc. 2019;8(13): e010874.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Glass DR, Tsai AG, Oliveria JP, Hartmann FJ, Kimmey SC, Calderon AA, Borges L, Glass MC, Wagar LE, Davis MM, et al. An integrated multi-omic single-cell atlas of human B cell identity. Immunity. 2020;53(1):217-232 e215.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Resta R, Yamashita Y, Thompson LF. Ecto-enzyme and signaling functions of lymphocyte CD73. Immunol Rev. 1998;161:95–109.

    Article  CAS  PubMed  Google Scholar 

  50. Miller RA, Luke JJ, Hu S, Mahabhashyam S, Jones WB, Marron T, Merchan JR, Hughes BGM, Willingham SB. Anti-CD73 antibody activates human B cells, enhances humoral responses and induces redistribution of B cells in patients with cancer. J Immunother Cancer. 2022. https://doi.org/10.1136/jitc-2022-005802.

    Article  PubMed  PubMed Central  Google Scholar 

  51. Antonioli L, Yegutkin GG, Pacher P, Blandizzi C, Hasko G. Anti-CD73 in cancer immunotherapy: awakening new opportunities. Trends Cancer. 2016;2(2):95–109.

    Article  PubMed  PubMed Central  Google Scholar 

  52. Lileikyte G, Bakochi A, Ali A, Moseby-Knappe M, Cronberg T, Friberg H, Lilja G, Levin H, Arman F, Kjellstrom S, et al. Serum proteome profiles in patients treated with targeted temperature management after out-of-hospital cardiac arrest. Intensive Care Med Exp. 2023;11(1):43.

    Article  PubMed  PubMed Central  Google Scholar 

  53. Cunningham CA, Coppler PJ, Skolnik AB. The immunology of the post-cardiac arrest syndrome. Resuscitation. 2022;179:116–23.

    Article  PubMed  Google Scholar 

  54. Cour M, Loufouat J, Paillard M, Augeul L, Goudable J, Ovize M, Argaud L. Inhibition of mitochondrial permeability transition to prevent the post-cardiac arrest syndrome: a pre-clinical study. Eur Heart J. 2011;32(2):226–35.

    Article  PubMed  Google Scholar 

  55. Cour M, Jahandiez V, Bochaton T, Venet F, Ovize M, Monneret G, Argaud L. Cyclosporine A prevents ischemia-reperfusion-induced lymphopenia after out-of-hospital cardiac arrest: a predefined sub-study of the CYRUS trial. Resuscitation. 2019;138:129–31.

    Article  PubMed  Google Scholar 

  56. Meyer MAS, Wiberg S, Grand J, Meyer ASP, Obling LER, Frydland M, Thomsen JH, Josiassen J, Moller JE, Kjaergaard J, et al. Treatment effects of interleukin-6 receptor antibodies for modulating the systemic inflammatory response after out-of-hospital cardiac arrest (The IMICA Trial): a double-blinded, placebo-controlled, single-center, randomized. Clin Trial Circ. 2021;143(19):1841–51.

    CAS  Google Scholar 

  57. Kleveland O, Kunszt G, Bratlie M, Ueland T, Broch K, Holte E, Michelsen AE, Bendz B, Amundsen BH, Espevik T, et al. Effect of a single dose of the interleukin-6 receptor antagonist tocilizumab on inflammation and troponin T release in patients with non-ST-elevation myocardial infarction: a double-blind, randomized, placebo-controlled phase 2 trial. Eur Heart J. 2016;37(30):2406–13.

    Article  CAS  PubMed  Google Scholar 

  58. Varvarousi G, Stefaniotou A, Varvaroussis D, Xanthos T. Glucocorticoids as an emerging pharmacologic agent for cardiopulmonary resuscitation. Cardiovasc Drugs Ther. 2014;28(5):477–88.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. Shah K, Mitra AR. Use of corticosteroids in cardiac arrest—a systematic review and meta-analysis. Crit Care Med. 2021;49(6):e642–50.

    Article  CAS  PubMed  Google Scholar 

  60. Mentzelopoulos SD, Zakynthinos SG, Tzoufi M, Katsios N, Papastylianou A, Gkisioti S, Stathopoulos A, Kollintza A, Stamataki E, Roussos C. Vasopressin, epinephrine, and corticosteroids for in-hospital cardiac arrest. Arch Intern Med. 2009;169(1):15–24.

    Article  CAS  PubMed  Google Scholar 

  61. Mentzelopoulos SD, Malachias S, Chamos C, Konstantopoulos D, Ntaidou T, Papastylianou A, Kolliantzaki I, Theodoridi M, Ischaki H, Makris D, et al. Vasopressin, steroids, and epinephrine and neurologically favorable survival after in-hospital cardiac arrest: a randomized clinical trial. JAMA. 2013;310(3):270–9.

    Article  PubMed  Google Scholar 

  62. Yu Y, Tang Z, Xie M, Li J, Hang CC, An L, Li C. Glucocorticoid receptor expression in patients with cardiac arrest in the early period after the return of spontaneous circulation: a prospective observational single-centre study. BMJ Open. 2022;12(9): e060246.

    Article  PubMed  PubMed Central  Google Scholar 

  63. Tahsili-Fahadan P, Farrokh S, Geocadin RG. Hypothermia and brain inflammation after cardiac arrest. Brain Circ. 2018;4(1):1–13.

    Article  PubMed  PubMed Central  Google Scholar 

  64. Boissady E, Kohlhauer M, Lidouren F, Hocini H, Lefebvre C, Chateau-Jouber S, Mongardon N, Deye N, Cariou A, Micheau P, et al. Ultrafast hypothermia selectively mitigates the early humoral response after cardiac arrest. J Am Heart Assoc. 2020;9(23): e017413.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  65. Bisschops LL, Hoedemaekers CW, Mollnes TE, van der Hoeven JG. Rewarming after hypothermia after cardiac arrest shifts the inflammatory balance. Crit Care Med. 2012;40(4):1136–42.

    Article  PubMed  Google Scholar 

  66. Beurskens CJ, Horn J, de Boer AM, Schultz MJ, van Leeuwen EM, Vroom MB, Juffermans NP. Cardiac arrest patients have an impaired immune response, which is not influenced by induced hypothermia. Crit Care. 2014;18(4):R162.

    Article  PubMed  PubMed Central  Google Scholar 

  67. Yamada Y, Ito M, Arai M, Hibino M, Tsujioka T, Harashima H. Challenges in promoting mitochondrial transplantation therapy. Int J Mol Sci. 2020. https://doi.org/10.3390/ijms21176365.

    Article  PubMed  PubMed Central  Google Scholar 

  68. Xu Y, Yu Y, Yang B, Hui J, Zhang C, Fang H, Bian X, Tao M, Lu Y, Shang Z. Extracellular mitochondrial components and effects on cardiovascular disease. DNA Cell Biol. 2021;40(9):1131–43.

    Article  PubMed  Google Scholar 

  69. Zhang Z, Yan C, Miao J, Pu K, Ma H, Wang Q. Muscle-derived mitochondrial transplantation reduces inflammation, enhances bacterial clearance, and improves survival in sepsis. Shock. 2021;56(1):108–18.

    Article  CAS  PubMed  Google Scholar 

  70. Hwang JW, Lee MJ, Chung TN, Lee HAR, Lee JH, Choi SY, Park YJ, Kim CH, Jin I, Kim SH, et al. The immune modulatory effects of mitochondrial transplantation on cecal slurry model in rat. Crit Care. 2021;25(1):20.

    Article  PubMed  PubMed Central  Google Scholar 

  71. Mokhtari B, Badalzadeh R. Mitochondria-targeted combination treatment strategy counteracts myocardial reperfusion injury of aged rats by modulating autophagy and inflammatory response. Mol Biol Rep. 2023;50(5):3973–83.

    Article  CAS  PubMed  Google Scholar 

  72. Lin MW, Fang SY, Hsu JC, Huang CY, Lee PH, Huang CC, Chen HF, Lam CF, Lee JS. Mitochondrial transplantation attenuates neural damage and improves locomotor function after traumatic spinal cord injury in rats. Front Neurosci. 2022;16: 800883.

    Article  PubMed  PubMed Central  Google Scholar 

  73. Moskowitzova K, Orfany A, Liu K, Ramirez-Barbieri G, Thedsanamoorthy JK, Yao R, Guariento A, Doulamis IP, Blitzer D, Shin B, et al. Mitochondrial transplantation enhances murine lung viability and recovery after ischemia-reperfusion injury. Am J Physiol Lung Cell Mol Physiol. 2020;318(1):L78–88.

    Article  CAS  PubMed  Google Scholar 

  74. Gollihue JL, Patel SP, Rabchevsky AG. Mitochondrial transplantation strategies as potential therapeutics for central nervous system trauma. Neural Regen Res. 2018;13(2):194–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  75. Wang Y, Ni J, Gao C, Xie L, Zhai L, Cui G, Yin X. Mitochondrial transplantation attenuates lipopolysaccharide-induced depression-like behaviors. Prog Neuropsychopharmacol Biol Psychiatry. 2019;93:240–9.

    Article  CAS  PubMed  Google Scholar 

  76. Lee JM, Hwang JW, Kim MJ, Jung SY, Kim KS, Ahn EH, Min K, Choi YS. Mitochondrial transplantation modulates inflammation and apoptosis, alleviating tendinopathy both in vivo and in vitro. Antioxidants (Basel). 2021. https://doi.org/10.3390/antiox10050696.

    Article  PubMed  PubMed Central  Google Scholar 

  77. Yu M, Wang D, Chen X, Zhong D, Luo J. BMSCs-derived mitochondria improve osteoarthritis by ameliorating mitochondrial dysfunction and promoting mitochondrial biogenesis in chondrocytes. Stem Cell Rev Rep. 2022;18(8):3092–111.

    Article  CAS  PubMed  Google Scholar 

  78. Yu SH, Kim S, Kim Y, Lee SE, Park JH, Cho G, Ha JC, Jung H, Lim SM, Han K, et al. Human umbilical cord mesenchymal stem cell-derived mitochondria (PN-101) attenuate LPS-induced inflammatory responses by inhibiting NFkappaB signaling pathway. BMB Rep. 2022;55(3):136–41.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  79. Ene HM, Karry R, Farfara D, Ben-Shachar D. Mitochondria play an essential role in the trajectory of adolescent neurodevelopment and behavior in adulthood: evidence from a schizophrenia rat model. Mol Psychiatry. 2023;28(3):1170–81.

    Article  PubMed  Google Scholar 

  80. Masuzawa A, Black KM, Pacak CA, Ericsson M, Barnett RJ, Drumm C, Seth P, Bloch DB, Levitsky S, Cowan DB, et al. Transplantation of autologously derived mitochondria protects the heart from ischemia-reperfusion injury. Am J Physiol Heart Circ Physiol. 2013;304(7):H966-982.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  81. Kaza AK, Wamala I, Friehs I, Kuebler JD, Rathod RH, Berra I, Ericsson M, Yao R, Thedsanamoorthy JK, Zurakowski D, et al. Myocardial rescue with autologous mitochondrial transplantation in a porcine model of ischemia/reperfusion. J Thorac Cardiovasc Surg. 2017;153(4):934–43.

    Article  PubMed  Google Scholar 

  82. Ramirez-Barbieri G, Moskowitzova K, Shin B, Blitzer D, Orfany A, Guariento A, Iken K, Friehs I, Zurakowski D, Del Nido PJ, et al. Alloreactivity and allorecognition of syngeneic and allogeneic mitochondria. Mitochondrion. 2019;46:103–15.

    Article  CAS  PubMed  Google Scholar 

  83. Nakamura Y, Lo EH, Hayakawa K. Placental mitochondria therapy for cerebral ischemia-reperfusion injury in mice. Stroke. 2020;51(10):3142–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  84. Zhang Z, Ma Z, Yan C, Pu K, Wu M, Bai J, Li Y, Wang Q. Muscle-derived autologous mitochondrial transplantation: a novel strategy for treating cerebral ischemic injury. Behav Brain Res. 2019;356:322–31.

    Article  CAS  PubMed  Google Scholar 

  85. Blitzer D, Guariento A, Doulamis IP, Shin B, Moskowitzova K, Barbieri GR, Orfany A, Del Nido PJ, McCully JD. Delayed transplantation of autologous mitochondria for cardioprotection in a porcine model. Ann Thorac Surg. 2020;109(3):711–9.

    Article  PubMed  Google Scholar 

  86. Doulamis IP, Guariento A, Duignan T, Kido T, Orfany A, Saeed MY, Weixler VH, Blitzer D, Shin B, Snay ER, et al. Mitochondrial transplantation by intra-arterial injection for acute kidney injury. Am J Physiol Renal Physiol. 2020;319(3):F403–13.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  87. Fang SY, Roan JN, Lee JS, Chiu MH, Lin MW, Liu CC, Lam CF. Transplantation of viable mitochondria attenuates neurologic injury after spinal cord ischemia. J Thorac Cardiovasc Surg. 2021;161(5):e337–47.

    Article  PubMed  Google Scholar 

  88. Al Amir Dache Z, Otandault A, Tanos R, Pastor B, Meddeb R, Sanchez C, Arena G, Lasorsa L, Bennett A, Grange T, et al. Blood contains circulating cell-free respiratory competent mitochondria. FASEB J. 2020;34(3):3616–30.

    Article  CAS  PubMed  Google Scholar 

  89. Stephens OR, Grant D, Frimel M, Wanner N, Yin M, Willard B, Erzurum SC, Asosingh K. Characterization and origins of cell-free mitochondria in healthy murine and human blood. Mitochondrion. 2020;54:102–12.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  90. Shi X, Zhao M, Fu C, Fu A. Intravenous administration of mitochondria for treating experimental Parkinson’s disease. Mitochondrion. 2017;34:91–100.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

Not applicable.

Funding

No funding was obtained for this study.

Author information

Authors and Affiliations

  1. Laboratory for Critical Care Physiology, Feinstein Institutes for Medical Research, Northwell Health System, Manhasset, NY, USA

    Tomoaki Aoki, Yusuke Endo, Eriko Nakamura, Cyrus E. Kuschner, Jacob Kazmi, Parmeshar Singh, Tai Yin, Lance B. Becker & Kei Hayashida

  2. Department of Emergency Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, USA

    Cyrus E. Kuschner, Lance B. Becker & Kei Hayashida

Authors
  1. Tomoaki Aoki
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yusuke Endo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Eriko Nakamura
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Cyrus E. Kuschner
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jacob Kazmi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Parmeshar Singh
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Tai Yin
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Lance B. Becker
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Kei Hayashida
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Concept and design: KH. Drafting manuscript: TA. Acquisition, analysis, and interpretation of the data: TA, YE, EN, CEK, JK, PS, TY, KH. Critical revision of the manuscript: LBB, KH. All authors have read and approved the manuscript.

Corresponding author

Correspondence to Kei Hayashida.

Ethics declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

All authors declare that they have no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Aoki, T., Endo, Y., Nakamura, E. et al. Therapeutic potential of mitochondrial transplantation in modulating immune responses post-cardiac arrest: a narrative review. J Transl Med 22, 230 (2024). https://doi.org/10.1186/s12967-024-05003-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s12967-024-05003-2

Keywords

Journal of Translational Medicine

ISSN: 1479-5876

Contact us